Description: Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Home Page: www.precipiodx.com
PRPO Technical Analysis
4 Science Park
New Haven,
CT
06511
United States
Phone:
203 787 7888
Officers
| Name | Title |
|---|---|
| Mr. Ilan Danieli | Founder, Pres, CEO & Director |
| Mr. Ahmed Zaki Sabet | Chief Operating Officer |
| Dr. Ayman Mohamed M.D. | Chief Technology Officer |
| Mr. Matthew Gage | Interim Chief Financial Officer |
| Ms. Miri Chiko-Radomski | Chief Legal Counsel & People Officer |
| Mr. Keith Meadors | Sr. VP of Products Division |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Providers & Services |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8422 |
| Price-to-Sales TTM: | 1.4963 |
| IPO Date: | 2000-07-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |